OVID
Ovid Therapeutics Inc. NASDAQ Listed May 5, 2017$2.50
+7.76%
vs $2.32
Mkt Cap $184.3M
52w Low $0.30
82.7% of range
52w High $2.96
50d MA $2.59
200d MA $1.90
P/E (TTM)
-7.2x
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.1x
ROE
-13.3%
P/FCF
-4.8x
RSI (14)
54.60
ATR (14)
$0.16
Beta
-0.03
50d MA
$2.59
200d MA
$1.90
Avg Volume
2.3M
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
1460 Broadway · New York City, NY 10036 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | BMO | -0.12 | -0.12 | +0.0% | 2.79 | -0.4% | +2.9% | -2.4% | +0.0% | -6.1% | -8.4% | — |
| Mar 18, 2026 | BMO | -0.10 | 0.06 | +160.0% | 2.30 | -0.4% | +0.0% | +13.9% | -2.7% | -5.1% | -0.8% | — |
| Nov 12, 2025 | BMO | -0.15 | -0.17 | -13.3% | 1.32 | -1.5% | -9.1% | +9.2% | -0.8% | +1.5% | -3.0% | — |
| Aug 13, 2025 | BMO | -0.16 | -0.06 | +62.5% | 0.86 | -5.6% | -2.1% | +15.4% | -3.8% | +0.8% | +1.1% | — |
| May 13, 2025 | BMO | -0.14 | -0.14 | +0.0% | 0.29 | +7.0% | +3.1% | +3.5% | -0.8% | -0.6% | -3.8% | — |
| Mar 11, 2025 | BMO | -0.16 | -0.13 | +18.8% | 0.49 | +6.1% | +2.0% | -12.0% | -1.4% | +7.4% | -1.2% | — |
| Nov 12, 2024 | BMO | -0.19 | -0.20 | -5.3% | 1.24 | -0.8% | -1.6% | -5.7% | -7.8% | -1.9% | -1.0% | — |
| Aug 13, 2024 | BMO | -0.22 | 0.12 | +154.5% | 0.88 | +0.7% | +15.0% | +11.9% | +0.0% | +0.9% | -0.9% | — |
| May 14, 2024 | BMO | -0.23 | -0.17 | +26.1% | 3.23 | +0.9% | +2.8% | -1.2% | -4.0% | -0.3% | -1.0% | — |
| Mar 8, 2024 | BMO | -0.17 | -0.22 | -29.4% | 3.08 | -0.3% | -4.5% | -3.7% | -0.4% | -2.5% | -1.1% | — |
| Nov 3, 2023 | BMO | -0.18 | -0.16 | +11.1% | 3.57 | +0.6% | -9.0% | +3.1% | +0.3% | -5.7% | +2.5% | — |
| Aug 4, 2023 | BMO | -0.21 | -0.18 | +14.3% | 3.50 | -0.3% | -6.9% | -0.9% | +2.2% | +6.7% | +2.8% | — |
| May 5, 2023 | AMC | -0.18 | -0.19 | -5.6% | 3.63 | -2.5% | -4.7% | +2.6% | +0.3% | -0.8% | +2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Wedbush | Maintains | Outperform → Outperform | — | $2.96 | $2.97 | +0.3% | -6.8% | +1.4% | +3.9% | -0.7% | -1.4% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.60 | $2.68 | +3.1% | +10.8% | -4.5% | +1.5% | +6.1% | -6.8% |
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $2.40 | $2.35 | -2.1% | +2.5% | -6.5% | -8.3% | +5.2% | -2.7% |
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $2.30 | $2.38 | +3.5% | +13.9% | -2.7% | -5.1% | -0.8% | +2.5% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.47 | $1.56 | +6.1% | +21.8% | +1.1% | -1.7% | +0.0% | -7.3% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.44 | +2.9% | +6.4% | +0.7% | +8.7% | +9.2% | +1.1% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.29 | $0.30 | +5.2% | +2.1% | -0.2% | +3.5% | -9.5% | +6.5% |
| Mar 24 | BTIG | Maintains | Buy → Buy | — | $0.43 | $0.44 | +3.5% | +4.5% | -3.2% | -5.4% | -6.9% | -7.6% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.43 | $0.44 | +3.5% | +4.5% | -3.2% | -5.4% | -6.9% | -7.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $0.49 | $0.52 | +6.1% | +2.0% | -12.0% | -1.4% | +7.4% | -1.2% |
| Jan 29 | Oppenheimer | Upgrade | Perform → Outperform | — | $0.73 | $0.72 | -1.1% | +1.9% | -5.6% | -5.2% | -0.4% | +0.3% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.10 | $1.07 | -2.7% | -3.6% | -2.8% | +11.7% | +1.7% | -2.6% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.18 | $1.18 | +0.0% | +0.0% | -5.1% | +0.9% | +0.0% | +1.8% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.14 | +0.9% | +0.9% | -0.9% | +5.3% | +1.7% | +0.0% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.06 | +0.0% | +0.0% | -0.9% | +0.0% | -1.0% | -4.8% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.87 | +1.2% | -10.3% | -2.8% | -0.8% | +12.1% | -0.7% |
| Jun 18 | BTIG | Maintains | Buy → Buy | — | $0.79 | $0.76 | -3.8% | -0.2% | -11.0% | +11.3% | +1.3% | -11.4% |
| Jun 18 | Citigroup | Maintains | Neutral → Neutral | — | $0.79 | $0.76 | -3.8% | -0.2% | -11.0% | +11.3% | +1.3% | -11.4% |
| Jun 18 | B. Riley Securities | Maintains | Buy → Buy | — | $0.79 | $0.76 | -3.8% | -0.2% | -11.0% | +11.3% | +1.3% | -11.4% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.79 | $0.76 | -3.8% | -0.2% | -11.0% | +11.3% | +1.3% | -11.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.32 | $3.33 | +0.3% | -1.2% | -4.0% | -0.3% | -1.0% | +3.9% |
| May 7 | Citigroup | Maintains | Neutral → Neutral | — | $3.02 | $3.00 | -0.7% | -0.7% | +3.0% | -1.3% | -1.6% | +0.7% |
| May 2 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $3.63 | $3.62 | -0.3% | -0.8% | +0.3% | +1.1% | -0.5% | -4.7% |
| Aug 29 | Citigroup | Maintains | Neutral → Neutral | — | $2.14 | $2.12 | -0.9% | -2.8% | -1.0% | -2.4% | -3.0% | +2.6% |
| May 20 | Citigroup | Maintains | Neutral → Neutral | — | $2.06 | $2.06 | +0.0% | +0.0% | -4.9% | -3.6% | -2.6% | -4.9% |
| Aug 25 | Citigroup | Maintains | Neutral → Neutral | — | $3.65 | $3.64 | -0.3% | -0.8% | -4.4% | +1.7% | -0.3% | +0.6% |
| Apr 20 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $3.70 | $3.59 | -3.0% | -2.7% | -0.3% | +1.9% | +0.3% | +6.0% |
| Dec 2 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $6.65 | $3.16 | -52.5% | -55.8% | -8.5% | -0.4% | -3.7% | -0.8% |
| Dec 2 | Citigroup | Downgrade | Buy → Neutral | — | $6.65 | $3.16 | -52.5% | -55.8% | -8.5% | -0.4% | -3.7% | -0.8% |
| Aug 26 | Citigroup | Maintains | Buy → Buy | — | $6.34 | $6.30 | -0.6% | -4.4% | -6.1% | +2.6% | -1.7% | -6.1% |
| Jun 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.43 | $5.75 | +5.9% | +35.7% | +0.4% | -1.8% | -3.2% | +12.4% |
| Sep 24 | Citigroup | Maintains | Buy → Buy | — | $2.47 | $2.60 | +5.3% | +25.5% | +13.2% | -4.0% | -8.3% | +4.9% |
| Sep 4 | RBC Capital | Maintains | Outperform → Outperform | — | $1.76 | $2.00 | +13.6% | +13.1% | -4.0% | +13.6% | -1.4% | +11.2% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.56 | $4.44 | -2.6% | -1.1% | +1.8% | -9.4% | -3.1% | +1.2% |
| Apr 20 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $10.14 | $10.36 | +2.2% | -1.6% | +0.7% | -0.7% | -3.0% | +3.5% |
| Mar 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.00 | $8.54 | +6.8% | +6.1% | -1.9% | -0.6% | +1.3% | +3.1% |
| May 30 | TD Cowen | Maintains | Outperform → Outperform | — | $14.48 | $14.50 | +0.1% | -7.3% | -5.0% | -8.4% | +4.0% | +2.1% |
| May 30 | William Blair | Maintains | Outperform → Outperform | — | $14.48 | $14.50 | +0.1% | -7.3% | -5.0% | -8.4% | +4.0% | +2.1% |
No insider trades available.
8-K
Ovid Therapeutics Inc. -- 8-K Filing
Jun 11
8-K · 5.02
!!! Very High
Ovid Therapeutics Inc. -- 8-K 5.02: Executive Change
Ovid Therapeutics appoints Anna Greka to its board of directors, potentially bringing new expertise and perspective to guide the company's strategy and operations.
Jun 3
8-K · 2.02
!! High
Ovid Therapeutics Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Ovid Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Ovid Therapeutics' Series A Warrants are being exercised, potentially increasing share dilution and providing capital to the company depending on warrant exercise terms and pricing.
Apr 20
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Governance / Corporate
OVID entered into an irrevable agreement with a major holder, likely involving voting rights or share commitments that could affect shareholder control and future governance decisions.
Mar 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 10,714,000 | $24M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 5,258,246 | $12M | New | Mar 2026 |
| 3 | Adar1 Capital Management, Llc | 4,544,113 | $10M | New | Mar 2026 |
| 4 | Ally Bridge Group (Ny) Llc | 2,818,459 | $6M | New | Mar 2026 |
| 5 | Susquehanna International Group, Llp | 1,947,594 | $4M | Added | Mar 2026 |
| 6 | Blue Owl Capital Holdings Lp | 1,904,666 | $4M | New | Mar 2026 |
| 7 | Millennium Management | 1,496,518 | $3M | Added | Mar 2026 |
| 8 | Point72 Asset Management | 1,320,610 | $3M | Reduced | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 1,256,869 | $3M | Added | Mar 2026 |
| 10 | Rosalind Advisors, Inc. | 1,107,994 | $2M | New | Mar 2026 |
| 11 | Renaissance Technologies Llc | 1,104,300 | $2M | Reduced | Mar 2026 |
| 12 | Propel Bio Management, Llc | 921,457 | $2M | New | Mar 2026 |
| 13 | Marshall Wace, Llp | 917,733 | $2M | Reduced | Mar 2026 |
| 14 | Walleye Capital Llc | 886,724 | $2M | Reduced | Mar 2026 |
| 15 | Wells Fargo & Company/mn | 713,625 | $2M | New | Mar 2026 |
| 16 | Jane Street Group, Llc | 883,867 | $1M | Added | Dec 2025 |
| 17 | Citadel Advisors Llc | 367,902 | $817K | Reduced | Mar 2026 |
| 18 | Sei Investments Co | 328,924 | $730K | New | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 290,432 | $645K | Reduced | Mar 2026 |
| 20 | Ubs Group Ag | 277,656 | $616K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 320,743 | $523K | Feb 2026 |
| 2 | EA Bridgeway Omni Small-Cap Value ETF | 91,234 | $203K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 112,670 | $184K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 82,602 | $135K | Feb 2026 |
| 5 | Invesco NASDAQ Future Gen 200 ETF | 37,116 | $60K | Feb 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 31,199 | $51K | Feb 2026 |
| 7 | Victory Extended Market Index Fund | 5,966 | $9K | Jan 2026 |
| 8 | Knights of Columbus U.S. ALL CAP INDEX FUND | 317 | $495 | Jan 2026 |
Valuation
Market Cap
$184.3M
Enterprise Value
$114.7M
P/E (TTM)
-7.23x
Forward P/E
—
PEG Ratio
0.20x
P/B
1.41x
P/S
25.88x
P/FCF
-4.81x
EV/EBITDA
—
Shares Out
73.7M
Financials (TTM)
Revenue
$7.1M
Net Income
-$24.2M
EBITDA
-$24.0M
Free Cash Flow
-$38.3M
Op Cash Flow
-$38.3M
EPS Basic
$-0.24
EPS Diluted
$-0.35
EPS Forward
$-0.49
Gross Margin
99.5%
Op Margin
—
Net Margin
-339.3%
Balance Sheet
Total Assets
$150.9M
Total Liab.
$20.3M
Total Equity
$130.7M
Cash
$69.6M
LT Debt
$0
Book Value/Sh
$1.77
Debt/Equity
0.10x
Current Ratio
10.91
Quick Ratio
10.91
Returns & Growth
ROE
-13.3%
ROA
-11.5%
ROIC
-29.5%
Rev Growth YoY
+1181.3%
EPS Growth YoY
+35.1%
Price Returns
2W
-2.5%
1M
-1.4%
3M
+67.5%
6M
+53.4%
12M
+902.9%
Technicals
52W High
$2.96
52W Low
$0.30
50d MA
$2.59
200d MA
$1.90
RSI (14)
54.60
ATR (14)
$0.16
Beta
-0.03
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.50
High
$4.00
Low
$3.00
Median
$3.50
Data updated apr 26, 2026 6:11pm
· Source: financialmodelingprep.com